<div id="readability-page-1"><div>Johnson Fistel Investigates Potential Board Fiduciary Duty Breaches in the Select Medical Take-Private TransactionShareholder rights law firm Johnson Fistel, PLLP has launched an investigation into whether the board members of Select Medical Holdings Corporation (NYSE: SEM) breached their fiduciary duties in connection with the proposed sale of the company to a consortium led by Robert A. Ortenzio, Martin F. Jackson, and Welsh, Carson, Anderson &amp; Stowe.If you own Select Medical shares and believe this proposed transaction undervalues your investment, please consider joining our investigation. To participate or learn more, you can click or copy and paste the following link: https://www.johnsonfistel.com/investigations/select-medical-holdings-corporation/Shareholders seeking more information may also contact lead analyst Jim Baker (jimb@johnsonfistel.com, 619-814-4471). If emailing, please include a phone number.BackgroundOn March 2, 2026, Select Medical announced that it had entered into a definitive merger agreement pursuant to which an entity affiliated with a consortium led by Robert A. Ortenzio, Executive Chairman, Co-Founder and Director of Select Medical, Martin F. Jackson, Senior Executive Vice President of Strategic Finance and Operations, and Welsh, Carson, Anderson &amp; Stowe will acquire all outstanding shares of Select Medical common stock not already owned by the consortium for $16.50 per share in cash.According to the announcement, Mr. Ortenzio, Mr. Jackson, and certain of their affiliates have agreed to roll over their equity to the parent entity of the surviving corporation in lieu of receiving the cash merger consideration. The Company further disclosed that the initial rollover participants collectively beneficially own approximately 11.8% of Select Medical’s outstanding common stock and have agreed to vote their shares in favor of adoption of the merger agreement.The transaction is expected to close in mid-2026, subject to customary closing conditions, including approval by Select Medical stockholders and approval by a majority of shares not held by the consortium or its affiliates.If consummated, the transaction would result in Select Medical becoming a privately held company, and its shares of common stock would be deregistered under applicable SEC rules and no longer listed on the New York Stock Exchange.Johnson Fistel’s investigation focuses on whether the Company’s board of directors conducted a fair process to maximize shareholder value and whether minority shareholders are receiving fair consideration for their shares.About Johnson Fistel, PLLP | Top Law Firm – Securities Fraud &amp; Investor RightsJohnson Fistel, PLLP is a nationally recognized shareholder-rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits and also assists foreign investors who purchased shares on U.S. exchanges. Stay informed about stock-drop news and learn how Johnson Fistel can help you recover losses by visiting www.johnsonfistel.com.AchievementsIn 2024, Johnson Fistel was ranked among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services. This recognition reflects the firm’s effectiveness in advocating for investors, having recovered approximately $90,725,000 for aggrieved clients in cases where it served as lead or co-lead counsel. This marks the eighth time the firm has been recognized as a top plaintiffs’ securities law firm in the United States, based on the total dollar value of final recoveries.Attorney advertising. Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content. <img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNjA1MDU1NzE1MDVyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNjA1MDU1NzE1MDVyMQ"/>Johnson Fistel, PLLP 501 W. Broadway, Suite 800 San Diego, CA 92101 James Baker, Investor Relations – or – Frank J. Johnson, Esq. (619) 814-4471 | jimb@johnsonfistel.com | fjohnson@johnsonfistel.comView source version on businesswire.com: https://www.businesswire.com/news/home/20260505571505/en/</div></div>

Select醫藥控股

2 倍做多納斯達克生物技術 ETF - ProShares

基因改革 ETF - ARK

Johnson Fistel，一家股東權益律師事務所，正在調查 Select Medical Holdings Corporation 董事會在其擬議出售給由 Robert A. Ortenzio 和 Martin F. Jackson 領導的財團過程中可能存在的信託責任違反行為。此次調查旨在確定董事會是否最大化了股東價值，以及少數股東是否得到了公平的對待。該交易於 2026 年 3 月 2 日宣佈，提議以每股 16.50 美元的價格收購股份，這可能使 Select Medical 成為一傢俬人公司。感興趣的股東可以加入調查以獲取更多信息

Johnson Fistel Investigates Potential Board Fiduciary Duty Breaches in the Select Medical Take-Private Transaction

MorningStar

標普生物技術 ETF - SPDR

Invesco Nasdaq Biotechnology ETF

納斯達克生物科技指數 ETF - iShares Nasdaq

紐交所高增長板生物技術指數 ETF - First Trust

動態生物技術與基因組 ETF - Invesco

標普全球醫療股指數 ETF - iShares

美國制藥 ETF - iShares

醫療業 ETF - Vanguard

生物科技 ETF - VanEck Vectors

標普生物技術 3 倍做多 - Direxion

醫療業 ETF - SPDR

醫藥突破 ETF - ALPS

Johnson Fistel 調查 Select Medical 私有化交易中可能存在的董事會受託責任違約問題